Samuel Zhang

Company: Gracell Biotechnologies

Job title: Chief Business Officer

Seminars:

Donor-Derived CAR-T Cell Therapy 11:30 am

Allo-SCT is a curative treatment option for high-risk leukemias. However, pts who progress after allo-SCT have limited treatment options. One potential solution is to use their healthy donors’ T cells to make CAR-Ts. This approach not only enables pts who would otherwise be ineligible for CAR-T cell therapy, but may also provide healthier CAR-T cells…Read more

day: Day 1: Pre-Clinical & Translational - Morning